MX2009003002A - Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco. - Google Patents

Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.

Info

Publication number
MX2009003002A
MX2009003002A MX2009003002A MX2009003002A MX2009003002A MX 2009003002 A MX2009003002 A MX 2009003002A MX 2009003002 A MX2009003002 A MX 2009003002A MX 2009003002 A MX2009003002 A MX 2009003002A MX 2009003002 A MX2009003002 A MX 2009003002A
Authority
MX
Mexico
Prior art keywords
methods
mucus clearance
pulmonary surfactant
pulmonary
surfactant formulations
Prior art date
Application number
MX2009003002A
Other languages
English (en)
Spanish (es)
Inventor
Mark E Johnson
Robert Segal
Thomas Hofmann
Robert J Capetola
Original Assignee
Discovery Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discovery Lab Inc filed Critical Discovery Lab Inc
Publication of MX2009003002A publication Critical patent/MX2009003002A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MX2009003002A 2006-09-19 2007-09-19 Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco. MX2009003002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84599106P 2006-09-19 2006-09-19
PCT/US2007/020260 WO2008036293A1 (en) 2006-09-19 2007-09-19 Pulmonary surfactant formulations and methods for promoting mucus clearance

Publications (1)

Publication Number Publication Date
MX2009003002A true MX2009003002A (es) 2009-06-01

Family

ID=38921793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003002A MX2009003002A (es) 2006-09-19 2007-09-19 Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.

Country Status (11)

Country Link
US (1) US8221772B2 (enExample)
EP (1) EP2063903A1 (enExample)
JP (1) JP2010503731A (enExample)
KR (1) KR20090060348A (enExample)
AU (1) AU2007297691B2 (enExample)
BR (1) BRPI0717177A2 (enExample)
CA (1) CA2663795A1 (enExample)
MX (1) MX2009003002A (enExample)
RU (1) RU2455021C2 (enExample)
WO (1) WO2008036293A1 (enExample)
ZA (1) ZA200902487B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
EA022786B1 (ru) 2009-07-31 2016-03-31 Этрис Гмбх Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
NZ607358A (en) * 2010-08-23 2015-04-24 Takeda Gmbh Humidified particles comprising a therapeutically active substance
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
GB201406225D0 (en) * 2014-04-07 2014-05-21 Hall Roderick L Treatment for respiratory disease
BR112017002356A2 (pt) * 2014-08-08 2017-11-28 Shanghai Hightide Biopharmaceutical Ltd composições de formulação líquida, dispositivos de entrega de medicamento e métodos para preparação e uso dos mesmos
US12702649B2 (en) * 2016-05-23 2026-08-11 University Of Iowa Research Foundation Method of treating cystic fibrosis airway disease
EP3484458A4 (en) * 2016-07-16 2020-04-15 Lauranell Harrison Burch METHOD FOR TREATING MUCOVISCIDOSIS AND OTHER DISEASES WITH EFFECT ON THE MUCOSA
US11096932B2 (en) 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance
EP3621979A1 (en) 2017-05-09 2020-03-18 VIB vzw Means and methods for treating bacterial infections
MX2020006634A (es) * 2017-12-21 2021-01-15 Civitas Therapeutics Inc Formulaciones de surfactantes para inhalacion.
US12427273B1 (en) 2020-05-15 2025-09-30 John E. Boyd Methods for treating respiratory distress and compositions for use in the same
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物
KR20250153517A (ko) 2024-04-18 2025-10-27 민현홍 신생아 호흡 곤란 증후군을 앓고 있는 조산아의 폐 전달을 개선하기 위한 미세기포 함유 에어로졸
WO2025231023A1 (en) * 2024-04-29 2025-11-06 Virginia Commonwealth University Aerosol surfactant therapy (ast) for respiratory distress syndrome (rds)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840527A (en) 1984-12-11 1998-11-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Recombinant alveolar surfactant protein
US4659805A (en) 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US4918161A (en) 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
IT1203873B (it) 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
AU625394B2 (en) 1987-11-04 1992-07-09 Byk Gulden Lomberg Chemische Fabrik Gmbh Alveolar surfactant proteins
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US4861756A (en) 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5238920A (en) 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
EP0458167B1 (en) 1990-05-21 1997-04-23 Abbott Laboratories Fatty acid-pulmonary surfactant conjugates
US5272252A (en) 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
WO1993021221A1 (en) 1992-04-10 1993-10-28 Abbott Laboratories Pulmonary surfactant protein fragments
US5302481A (en) 1993-06-07 1994-04-12 Xerox Corporation Toner compositions with negative charge enhancing complexes
ES2189825T3 (es) 1993-12-08 2003-07-16 Mitsubishi Pharma Corp Nuevo peptido sintetico, tensioactivo pulmonar que lo contiene y remedio para el sindrome de malestar respiratorio.
DE4418936A1 (de) 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
DE4434629C1 (de) 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US5925334A (en) 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US7198635B2 (en) * 2000-10-17 2007-04-03 Asthmatx, Inc. Modification of airways by application of energy
ATE254473T1 (de) * 1998-12-22 2003-12-15 Bayer Ag Verwendung eines serinproteaseinhibitors vom kunitz-typ zur beschleunigung der schleimauflöserate
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
RU2149014C1 (ru) 1999-07-01 2000-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения острых бронхопневмоний, осложненных ателектазом
RU2149015C1 (ru) * 1999-07-01 2000-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения постнатальных пневмоний у новорожденных
DE10006179A1 (de) 2000-02-11 2001-08-23 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe und Behandlung von chronischen Lungenerkrankungen
US6660833B1 (en) 2000-02-29 2003-12-09 Harbor-Ucla Research And Education Institute Respiratory distress syndrome therapy with peptide analogs of human SP-B
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
PT1280520E (pt) * 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
EP1238680B1 (en) 2001-03-05 2003-12-10 Ivo Pera Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract
CA2445516C (en) 2001-04-26 2007-11-20 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
RU2213746C1 (ru) 2002-02-15 2003-10-10 Научно-исследовательский институт физико-химической медицины Компонент, обеспечивающий поверхностно-активные свойства композиций - аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний
RU2198670C1 (ru) 2002-02-19 2003-02-20 ООО "Биосурф" Способ получения сурфактанта из легких крупного рогатого скота
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
AU2004296206A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
CA2567334A1 (en) * 2004-05-20 2005-12-08 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
CA2575513C (en) * 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
JP2008511398A (ja) 2004-08-27 2008-04-17 ディスカバリー ラボラトリーズ，インコーポレイテッド 非侵襲性肺送出のための方法、システム及び装置
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
JP2008526868A (ja) * 2005-01-06 2008-07-24 ディスカバリー ラボラトリーズ，インコーポレイテッド 表面活性剤処置療法

Also Published As

Publication number Publication date
WO2008036293A1 (en) 2008-03-27
JP2010503731A (ja) 2010-02-04
CA2663795A1 (en) 2008-03-27
ZA200902487B (en) 2010-07-28
AU2007297691B2 (en) 2013-12-19
BRPI0717177A2 (pt) 2013-10-08
RU2009114825A (ru) 2010-10-27
US8221772B2 (en) 2012-07-17
US20080199410A1 (en) 2008-08-21
EP2063903A1 (en) 2009-06-03
KR20090060348A (ko) 2009-06-11
RU2455021C2 (ru) 2012-07-10
AU2007297691A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2007125545A3 (en) Transmucosal composition
MY143795A (en) Tetrahydropyridoindole derivatives
PE20080658A1 (es) Formulaciones de metilnaltrexona en forma de polvo seco
CR10408A (es) Composiciones novedosas para el trastornos del cabello y procedimiento de preparacion de las mismas
WO2008151235A3 (en) Compositions for delivering medicaments into the lungs, uses thereof
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
MX2017010220A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
MX2010004388A (es) Formulaciones de hormona paratiroidea y usos de las mismas.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
CR10495A (es) Composicion que comprende por lo menos un alcohol alifatico superior y un extracto de griffonia simplicifolia
PL1933809T3 (pl) Kompozycje do dostarczania donosowego
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX350595B (es) Composiciones organicas para tratar enfermedades relacionadas con beta-enac.
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
MX2009005798A (es) Recuperacion de apoplejia.
WO2008099144A3 (en) Tgf-beta stimulant and further agent to reduce side effects
WO2009000551A8 (de) Verwendung einer synergistischen zusammensetzung als therapeutisches mittel oder desinfektionsmittel
IL186058A0 (en) Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2009102808A3 (en) Doxorubicin adjuvants to reduce toxicity and methods for using the same
TW200730190A (en) New combination to treat liver fibrosis

Legal Events

Date Code Title Description
FG Grant or registration